{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'May result in inpatient hospitalization or prolongation of existing hospitalization.', 'Hospitalization is defined as any inpatient admission (even if less than', '24 hours). Inpatient admission does not include the following:', '-', 'Emergency room department visits.', '-', 'Outpatient/same day/ambulatory procedures/observation/short-stay units.', '-', 'Hospice facilities/respite care.', '- Rehabilitation facilities.', '-', 'NOTE: In general, hospitalization signifies that the subject has been detained', '(usually involving at least an overnight stay) at the hospital or emergency ward', 'for observation and/or treatment that would not have been appropriate in the', \"physician's office or outpatient setting. Complications that occur during\", 'hospitalization are AEs. If a complication prolongs hospitalization or fulfills any', 'other serious criteria, the event is serious. When in doubt as to whether', '\"hospitalization\" occurred or was necessary, the AE should be considered serious.', '- Hospitalization for elective treatment of a pre-existing condition that did not', 'worsen from baseline is not considered an AE.', '-', 'A hospitalization planned prior to study enrollment is to be considered a', 'therapeutic intervention and not the result of a new SAE. If the planned', 'hospitalization or procedure is executed as planned, it will be recorded in the', \"subject's medical history or procedures. However, if the event/condition worsens\", 'during the study, it must be reported as an AE.', '-', 'Emergency room visits that do not result in a hospital admission should be', 'evaluated for one of the other serious outcomes (eg, life-threatening; required', 'intervention to prevent permanent impairment or damage; other serious medically', 'important event).', 'Results in disability/incapacity.', '-', \"NOTE: The term disability means a substantial disruption of a person's ability to\", 'conduct normal life functions. This definition is not intended to include', 'experiences of relatively minor medical significance such as uncomplicated', 'headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg,', 'sprained ankle) that may interfere or prevent everyday life functions but do not', 'constitute a substantial disruption.', 'Is a congenital anomaly/birth defect.', 'Medical or scientific judgment should be exercised in deciding whether reporting is', 'appropriate in other situations, such as important medical events that may not be', 'immediately life-threatening or result in death or hospitalization but may jeopardize', 'the subject or may require medical or surgical intervention to prevent one of the other', 'outcomes listed in the above definition. These should also be considered serious.', 'Examples of such events are invasive or malignant cancers, intensive treatment in an', 'emergency room or at home for allergic bronchospasm, blood dyscrasias or', 'Glenmark', 'CONFIDENTIAL', 'Page 52 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'convulsions that do not result in hospitalization, or development of drug dependency', 'or drug abuse.', '11.3.', 'Relationship to Study Drug', 'The relationship of AEs to study medication is classified as follows:', 'Not Related: A causal relationship between the study drug and the AE is not a', 'reasonable possibility.', 'Related: A causal relationship between the study drug and the AE is a reasonable', 'possibility.', 'Items to be considered when assessing the relationship of an AE to the study drug are:', 'Temporal relationship of the onset of the event to the initiation of the study drug.', 'The course of the event, especially the effect of discontinuation of study drug or', 'reintroduction of study drug, as applicable.', 'Whether the event is known to be associated with the study drug or with other similar', 'treatments.', 'The presence of risk factors in the study subject known to increase the occurrence of', 'the event.', 'The presence of non-study drug-related factors that are known to be associated with', 'the occurrence of the event.', 'For each AE, the Investigator should answer the following question with Yes or No:', 'Was there a reasonable possibility (evidence) that the drug caused the AE?', '- A reasonable possibility means that there are facts (evidence) or arguments to', 'suggest a causal relationship.', '- NOTE: For subjects that have not started receiving study medication, or placebo', 'run-in phase medications, the answer must be no.', '11.4.', 'Recording Adverse Events', '11.4.1.', 'Collection of Adverse Events', 'The Investigator or site staff is responsible for detecting, documenting and reporting events that', 'meet the definition of an AE or SAE.', 'AEs will be collected from the time of signing the informed consent form (ICF) until the follow', 'up contact.', 'SAEs will be collected over the same time period as stated above for AEs. However, any SAEs', 'assessed as related to study participation (eg, study drug, protocol mandated procedures, invasive', 'tests, or change in existing therapy) or related to a concomitant medication that is a Glenmark', 'product, will be recorded from the time a subject consents to participate in the study up to and', 'including any follow up contact. All SAEs will be reported to the Sponsor within 24 hours, as', 'indicated in Section 11.5.', 'Glenmark', 'CONFIDENTIAL', 'Page 53 of 90']\n\n###\n\n", "completion": "END"}